Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cidara Therapeutics (CDTX) Shares Outstanding (Weighted Average): 2014-2024

Historic Shares Outstanding (Weighted Average) for Cidara Therapeutics (CDTX) over the last 11 years, with Dec 2024 value amounting to $7.0 million.

  • Cidara Therapeutics' Shares Outstanding (Weighted Average) rose 260.29% to $25.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $25.4 million, marking a year-over-year increase of 260.29%. This contributed to the annual value of $7.0 million for FY2024, which is 55.84% up from last year.
  • According to the latest figures from FY2024, Cidara Therapeutics' Shares Outstanding (Weighted Average) is $7.0 million, which was up 55.84% from $4.5 million recorded in FY2023.
  • In the past 5 years, Cidara Therapeutics' Shares Outstanding (Weighted Average) registered a high of $7.0 million during FY2024, and its lowest value of $2.2 million during FY2020.
  • Its 3-year average for Shares Outstanding (Weighted Average) is $5.0 million, with a median of $4.5 million in 2023.
  • Data for Cidara Therapeutics' Shares Outstanding (Weighted Average) shows a peak YoY spiked of 55.84% (in 2024) over the last 5 years.
  • Over the past 5 years, Cidara Therapeutics' Shares Outstanding (Weighted Average) (Yearly) stood at $2.2 million in 2020, then soared by 51.77% to $3.3 million in 2021, then rose by 7.40% to $3.6 million in 2022, then rose by 26.27% to $4.5 million in 2023, then surged by 55.84% to $7.0 million in 2024.